

Drug Utilization Review (DUR) Meeting Minutes
December 7, 2009

Members Present: Patricia Churchill, Norman Byers, Carrie Sorenson, Greg Pfister, Jeffrey Hostetter, John Savageau, Carlotta McCleary, David Clinkenbeard, Steve Irsfeld, Russ Sobotta, James Carlson, Cheryl Huber

Members Absent: Todd Twogood, Leann Ness, Kim Krohn

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Chair, J. Hostetter called the meeting to order at 1:10 pm. Chair, J. Hostetter asked for a motion to approve the minutes from the September meeting. G. Pfister moved that the minutes be approved and J. Savageau seconded the motion. Chair, J. Hostetter called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce informed the board that the budget for the next biennium would be approximately 50 million dollars. The number of recipients eligible for Medicaid benefits has increased to approximately 60 thousand. This may be related to new legislation passed this session allowing continuous eligibility for children.

Hemophilia Second Review

At the September meeting a motion was made to place medications used to treat hemophilia on prior authorization. This is the second review. There was no public comment. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Sancuso Second Review

At the September meeting a motion was made to place Sancuso on prior authorization. This is the second review. There was no public comment. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Relistor Second Review

At the September meeting a motion was made to place Relistor on prior authorization. This is the second review. There was no public comment. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Nuvigil Second Review

At the September meeting a motion was made to place Nuvigil on prior authorization. This is the second review. There was no public comment. A clarification was made to the form and criteria that Nuvigil will need to be prescribed for an approved indication and a patient will need to fail a trial of Provigil before a prior authorization will be approved for Nuvigil. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Nucynta Second Review

At the September meeting a motion was made to place Nucynta on prior authorization. This is the second review. There was no public comment. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Solodyn, Oracea, Oxycontin, Vusion, and Short-acting beta-agonist forms and criteria were reviewed. No changes were made to the forms or criteria.

Review of Top Drugs and Drug Classes

B. Joyce reviewed the top drugs and drug classes with Board members. When reviewing the top classes by claims cost, the classes that are in the top 5 include antipsychotics, anticonvulsants, antidepressants, cerebral stimulants, and amphetamines. All of these classes are exempt from prior authorization because of legislation. Board members reviewed a list of the top classes by number of claims and the top classes include antidepressants, opiate agonists, anticonvulsants, sedative-hypnotics and antipsychotics. The board has placed Oxycontin (which is an opiate agonist) and Sedative-Hypnotics on prior authorization, but because of legislation the board is unable to place antidepressants, anticonvulsants and antipsychotics on prior authorization. Board members were asked to review these lists prior to the next meeting and give the Department ideas for educational endeavors or candidates for prior authorization.

Stimulant Utilization in children ≤ 5

B. Joyce reviewed stimulant medication utilization in children ≤ 5 . The number of recipients in this group grew from zero in 2003 to 85 during the first half of 2009. Board members discussed that more children are in preschool and all day kindergarten. C. McCleary also mentioned that screenings are being performed on a wider scale than in the past.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. N. Byers moved to approve the new criteria and J. Savageau seconded the motion. Chair, J. Hostetter called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held March 9, 2010. N. Byers made a motion to adjourn the meeting. C. Huber seconded. The motion passed with no audible dissent. Chair J. Hostetter adjourned the meeting at 2:23 pm.